Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity
Chushu Li, Han Yao, Huanbin Wang, et al.
Oncogene (2020) Vol. 40, Iss. 6, pp. 1128-1146
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells
Qingyu Lin, Xingwen Wang, Ying Hu
Cancer Letters (2023) Vol. 569, pp. 216318-216318
Open Access | Times Cited: 53
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Yazhen Wang, Zhou Yang, Lianyi Yang, et al.
Advanced Science (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 24
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 9
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma
Dantong Sun, Helei Hou, Feiyue Feng, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Calpain as a therapeutic target in cancer
Іван Шаповалов, Danielle Harper, Peter A. Greer
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 3, pp. 217-231
Open Access | Times Cited: 38
Calcium and calcium-related proteins in endometrial cancer: opportunities for pharmacological intervention
Ting Huang, Jingyi Zhou, Jianliu Wang
International Journal of Biological Sciences (2022) Vol. 18, Iss. 3, pp. 1065-1078
Open Access | Times Cited: 29
The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy
Md Rakibul Alam, Md Mizanur Rahman, Zhiguo Li
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 321-334
Open Access | Times Cited: 21
Inhibition of CK2/ING4 Pathway Facilitates Non‐Small Cell Lung Cancer Immunotherapy
Qian Gou, Huiqing Chen, Mingjun Chen, et al.
Advanced Science (2023) Vol. 10, Iss. 34
Open Access | Times Cited: 18
Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy
José L. Blaya-Cánovas, Carmen Griñán‐Lisón, Isabel Blancas, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents
Feng Zhang, Ruiya Jiang, Shishi Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116267-116267
Closed Access | Times Cited: 6
Zosuquidar Promotes Antitumor Immunity by Inducing Autophagic Degradation of PD‐L1
Ling Ding, Hongjie Guo, Jie Zhang, et al.
Advanced Science (2024) Vol. 11, Iss. 41
Open Access | Times Cited: 5
Metabolomic Analysis, Antiproliferative, Anti-Migratory, and Anti-Invasive Potential of Amlodipine in Lung Cancer Cells
Mohammad A. Y. Alqudah, Mahmoud Mohammad Yaseen, Karem H. Alzoubi, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 1215-1229
Open Access
Autophagy in tumor immune escape and immunotherapy
Huan Wang, Peng Sun, Xijing Yuan, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Amlodipine with letrozole as maintenance post-chemotherapy: targeting calcium calcineurin calmodulin pathway and aromatase inhibitor in disseminated endometrioid adenocarcinoma of the endometrium—a case report
Mukul Arvind Gharote, Amruta Ashok Deshpande, Anjali Kale
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Amlodipine with letrozole as maintenance post chemotherapy –targeting calcium calcinuerin calmodulin pathway and aromatase inhibitor indisseminated Endometrioid adenocarcinoma of the endometrium a – A case report
Mukul Arvind Gharote, Amruta Ashok Deshpande, Aditya Kale
Research Square (Research Square) (2025)
Closed Access
Metal-modulated T cell antitumor immunity and emerging metalloimmunotherapy
Peiyun Liao, Ying Zhou, Yingqi Qiu, et al.
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 2
Closed Access
The Role of Ion Channels in Cervical Cancer Progression: From Molecular Biomarkers to Diagnostic and Therapeutic Innovations
Elżbieta Bartoszewska, Melania Czapla, Katarzyna Rakoczy, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1538-1538
Open Access
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Chushu Li, Hao Chi, Shouyan Deng, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002443-e002443
Open Access | Times Cited: 27
The immunomodulatory effects of antihypertensive therapy: A review
Dominik Felkle, Mateusz Jarczyński, Konrad Kaleta, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 153, pp. 113287-113287
Open Access | Times Cited: 17
Temsirolimus Enhances Anti-Cancer Immunity by Inducing Autophagy-Mediated Degradation of the Secretion of Small Extracellular Vesicle PD-L1
Seong‐Sik Park, Jong‐In Kim, Chan‐Hyeong Lee, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4081-4081
Open Access | Times Cited: 17
Hydrogel-mediated tumor T cell infiltration and immune evasion to reinforce cancer immunotherapy
Guixiang Xu, Kai Liu, Xiangwu Chen, et al.
Nanoscale Horizons (2023) Vol. 9, Iss. 2, pp. 295-304
Closed Access | Times Cited: 8
Azelnidipine nanoparticles break calcium homeostasis and induce severe ER stress combined with medroxyprogesterone acetate for endometrial cancer therapy
Ting Huang, Jingyi Zhou, Lingpu Zhang, et al.
Nano Today (2022) Vol. 47, pp. 101682-101682
Closed Access | Times Cited: 13
Design, synthesis and biological evaluation of new dihydropyridine derivatives as PD-L1 degraders for enhancing antitumor immunity
Chenghao Pan, Mengxin Luo, Yang Lu, et al.
Bioorganic Chemistry (2022) Vol. 125, pp. 105820-105820
Closed Access | Times Cited: 12
Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
Xavier Thuru, Romain Magnez, Hassiba El-Bouazzati, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3368-3368
Open Access | Times Cited: 12
New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer
Zhi Li, Xi Yu, Zeting Yuan, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189152-189152
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top